Monte Rosa Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.08B
- P/E (TTM)
- –
- Dividend yield
- –
About Monte Rosa Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops molecular glue degraders to selectively eliminate disease-associated proteins using cellular degradation mechanisms. The company designs small molecule therapies across immunology, inflammation, cardiology, and oncology through its proprietary QuEEN discovery platform. Its clinical-stage pipeline includes MRT-6160 for immune-mediated diseases, MRT-8102 for inflammasome-driven inflammatory conditions, and MRT-2359 for metastatic castration-resistant prostate cancer. Because the company currently has no commercial product sales, its primary counterparties are pharmaceutical collaborators, such as Novartis and Roche, which license and develop its drug candidates.
The company maintains research and development operations centered around an internal chemical library that includes more than 1,000 unique scaffolds and over 75,000 distinct molecular glue compounds. Its operational reach and business partnerships include activities in the United States and Switzerland. Monte Rosa Therapeutics is headquartered at its principal executive offices in Boston, Massachusetts.
Summary of the business section of Monte Rosa Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Monte Rosa Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- 321 Harrison Avenue, Suite 900 02118
- Phone
- (617) 949-2643
- Employees
- 150, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- GLUE
- Exchange
- Nasdaq
- IPO date
- Jun 25, 2021
- Shares outstanding
- 85M, Jul 31, 2026
- Public float
- $212.00M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1826457
- CUSIP
- 61225M102
- ISIN
- US61225M1027
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Markus Warmuth | President & CEO, Director | 585,038 |
| Jennifer Champoux | Chief Operating Officer | 66,722 |
| Sharon Townson | Chief Scientific Officer | 68,245 |
| Filip Janku | Chief Medical Officer | 60,612 |
| Philip Nickson | Chief Business & Legal Officer | 55,000 |
| Matthew Bowen | Principal Accounting Officer | 21,604 |
| Edmund Dunn | Principal Accounting Officer | 22,554 |
| Ali Behbahani | Director | 6,707,298 |
| Anthony M. Manning | Director | 0 |
| Eric A. Hughes | Director | – |
| Kimberly Blackwell | Director | – |
| Christine Siu | Director | – |
| Jan Skvarka | Director | – |
| Andrew N. Schiff | Director | – |
| Chandra P. Leo | Director | 10,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 150 full-time employees, of which 71 have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 25, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 21, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |